Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Gynecology

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 58 articles: HTML format

Single Articles

February 2023
1. WALKER TDJ, Faraahi ZF, Price MJ, Hawarden A, et al
   The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome.
   Br J Cancer. 2023 Feb 21. doi: 10.1038/s41416-023-02168.
   PubMed     Abstract available
   
   
   
2. NJOKU K, Pierce A, Geary B, Campbell AE, et al
   Quantitative SWATH-based proteomic profiling of urine for the identification of endometrial cancer biomarkers in symptomatic women.
   Br J Cancer. 2023 Feb 17. doi: 10.1038/s41416-022-02139.
   PubMed     Abstract available
   
   
   
3. GUFFANTI F, Alvisi MF, Anastasia A, Ricci F, et al
   Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
   Br J Cancer. 2023 Feb 16. doi: 10.1038/s41416-023-02205.
   PubMed    
   
   
   
4. ASAMI Y, Kobayashi Kato M, Hiranuma K, Matsuda M, et al
   Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer.
   Br J Cancer. 2023 Feb 16. doi: 10.1038/s41416-023-02203.
   PubMed     Abstract available
   
   
   
5. COLOMBO N, Gadducci A, Sehouli J, Rulli E, et al
   INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 m
   Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-022-02108.
   PubMed     Abstract available
   
   
   
6. LEYDEN GM, Greenwood MP, Gaborieau V, Han Y, et al
   Disentangling the aetiological pathways between body mass index and site-specific cancer risk using tissue-partitioned Mendelian randomisation.
   Br J Cancer. 2023;128:618-625.
   PubMed     Abstract available
   
   
   January 2023
7. KRALJ J, Pernar Kovac M, Dabelic S, Polancec DS, et al
   Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT.
   Br J Cancer. 2023 Jan 30. doi: 10.1038/s41416-023-02140.
   PubMed     Abstract available
   
   
   
8. VERMIJ L, Jobsen JJ, Leon-Castillo A, Brinkhuis M, et al
   Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
   Br J Cancer. 2023 Jan 23. doi: 10.1038/s41416-023-02141.
   PubMed     Abstract available
   
   
   
9. TAKAMATSU S, Yoshihara K, Baba T, Shimada M, et al
   Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.
   Br J Cancer. 2023 Jan 2. doi: 10.1038/s41416-022-02122.
   PubMed     Abstract available
   
   
   December 2022
10. SANDVEI MS, Pinborg A, Gissler M, Bergh C, et al
    Risk of ovarian cancer in women who give birth after assisted reproductive technology (ART)-a registry-based Nordic cohort study with follow-up from first pregnancy.
    Br J Cancer. 2022 Dec 22. doi: 10.1038/s41416-022-02097.
    PubMed     Abstract available
    
    
    
11. IBRAHIM SL, Abed MN, Mohamed G, Price JC, et al
    Inhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel.
    Br J Cancer. 2022 Dec 16. doi: 10.1038/s41416-022-02095.
    PubMed     Abstract available
    
    
    
12. COSTA S, Verberckmoes B, Castle PE, Arbyn M, et al
    Offering HPV self-sampling kits: an updated meta-analysis of the effectiveness of strategies to increase participation in cervical cancer screening.
    Br J Cancer. 2022 Dec 14. doi: 10.1038/s41416-022-02094.
    PubMed     Abstract available
    
    
    
13. KRISTELEIT RS, Drew Y, Oza AM, Domchek SM, et al
    Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
    Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02022.
    PubMed     Abstract available
    
    
    
14. BERG HF, Engerud H, Myrvold M, Lien HE, et al
    Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value.
    Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02063.
    PubMed     Abstract available
    
    
    
15. MURUMAGI A, Ungureanu D, Khan S, Arjama M, et al
    Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
    Br J Cancer. 2022 Dec 7. doi: 10.1038/s41416-022-02067.
    PubMed     Abstract available
    
    
    November 2022
16. BAX HJ, Chauhan J, Stavraka C, Santaolalla A, et al
    Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes.
    Br J Cancer. 2022 Nov 19. doi: 10.1038/s41416-022-02031.
    PubMed     Abstract available
    
    
    
17. WEIR A, Kang EY, Meagher NS, Nelson GS, et al
    Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.
    Br J Cancer. 2022 Nov 2. pii: 10.1038/s41416-022-02014.
    PubMed     Abstract available
    
    
    September 2022
18. OCHS-BALCOM HM, Johnson C, Guertin KA, Qin B, et al
    Racial differences in the association of body mass index and ovarian cancer risk in the OCWAA Consortium.
    Br J Cancer. 2022 Sep 22. pii: 10.1038/s41416-022-01981.
    PubMed     Abstract available
    
    
    
19. CHEN Y, Wang DD, Wu YP, Su D, et al
    Correction To: MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.
    Br J Cancer. 2022 Sep 15. pii: 10.1038/s41416-022-01984.
    PubMed    
    
    
    
20. ABIKO K, Hamanishi J, Matsumura N, Mandai M, et al
    Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after "IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer".
    Br J Cancer. 2022 Sep 6. pii: 10.1038/s41416-022-01960.
    PubMed     Abstract available
    
    
    August 2022
21. AASBO G, Trope A, Nygard M, Christiansen IK, et al
    HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01954.
    PubMed     Abstract available
    
    
    
22. GAHLAWAT AW, Witte T, Haarhuis L, Schott S, et al
    A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis.
    Br J Cancer. 2022 Aug 5. pii: 10.1038/s41416-022-01925.
    PubMed     Abstract available
    
    
    July 2022
23. MUSACCHIO L, Califano D, Bartoletti M, Arenare L, et al
    Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
    Br J Cancer. 2022 Jul 22. pii: 10.1038/s41416-022-01897.
    PubMed     Abstract available
    
    
    
24. NICHOLSON HA, Sawers L, Clarke RG, Hiom KJ, et al
    Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.
    Br J Cancer. 2022 Jul 1. pii: 10.1038/s41416-022-01899.
    PubMed     Abstract available
    
    
    June 2022
25. SASAMOTO N, Wang T, Townsend MK, Eliassen AH, et al
    Pre-diagnosis and post-diagnosis dietary patterns and survival in women with ovarian cancer.
    Br J Cancer. 2022 Jun 27. pii: 10.1038/s41416-022-01901.
    PubMed     Abstract available
    
    
    
26. BEINSE G, Just PA, Le Frere Belda MA, Laurent-Puig P, et al
    Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    Br J Cancer. 2022 Jun 25. pii: 10.1038/s41416-022-01900.
    PubMed     Abstract available
    
    
    
27. KAMAT K, Krishnan V, Dorigo O
    Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.
    Br J Cancer. 2022 Jun 24. pii: 10.1038/s41416-022-01887.
    PubMed     Abstract available
    
    
    
28. HERBST J, Pantel K, Effenberger K, Wikman H, et al
    Clinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions.
    Br J Cancer. 2022 Jun 20. pii: 10.1038/s41416-022-01868.
    PubMed     Abstract available
    
    
    
29. BRANTLEY KD, Zeleznik OA, Dickerman BA, Balasubramanian R, et al
    A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses' Health Studies.
    Br J Cancer. 2022 Jun 18. pii: 10.1038/s41416-022-01873.
    PubMed     Abstract available
    
    
    
30. HOLLIS RL, Croy I, Churchman M, Bartos C, et al
    Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01874.
    PubMed     Abstract available
    
    
    
31. KOTSOPOULOS J, Zamani N, Rosen B, McLaughlin JR, et al
    Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer.
    Br J Cancer. 2022 Jun 16. pii: 10.1038/s41416-022-01840.
    PubMed     Abstract available
    
    
    
32. DI MARTINO E, Smith L, Bradley SH, Hemphill S, et al
    Incidence trends for twelve cancers in younger adults-a rapid review.
    Br J Cancer. 2022;126:1374-1386.
    PubMed     Abstract available
    
    
    May 2022
33. MENON U, Weller D, Falborg AZ, Jensen H, et al
    Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP).
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01844.
    PubMed     Abstract available
    
    
    
34. CHEN T, Yu T, Zhuang S, Geng Y, et al
    Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01836.
    PubMed     Abstract available
    
    
    
35. EL HELALI A, Plummer R, Jayson GC, Coyle VM, et al
    A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
    Br J Cancer. 2022 May 14. pii: 10.1038/s41416-022-01780.
    PubMed     Abstract available
    
    
    April 2022
36. CREMONA M, Vandenberg CJ, Farrelly AM, Madden SF, et al
    BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
    Br J Cancer. 2022 Apr 30. pii: 10.1038/s41416-022-01823.
    PubMed     Abstract available
    
    
    
37. JI M, Jiang S, Zhao J, Wan X, et al
    Efficacies of FAEV and EMA/CO regimens as primary treatment for gestational trophoblastic neoplasia.
    Br J Cancer. 2022 Apr 22. pii: 10.1038/s41416-022-01809.
    PubMed     Abstract available
    
    
    
38. KOIZUME S, Takahashi T, Nakamura Y, Yoshihara M, et al
    Lipophagy-ICAM-1 pathway associated with fatty acid and oxygen deficiencies is involved in poor prognoses of ovarian clear cell carcinoma.
    Br J Cancer. 2022 Apr 21. pii: 10.1038/s41416-022-01808.
    PubMed     Abstract available
    
    
    
39. SHAKFA N, Li D, Nersesian S, Wilson-Sanchez J, et al
    The STING pathway: Therapeutic vulnerabilities in ovarian cancer.
    Br J Cancer. 2022 Apr 5. pii: 10.1038/s41416-022-01797.
    PubMed     Abstract available
    
    
    
40. KONSTANTINOPOULOS PA, Cheng SC, Supko JG, Polak M, et al
    Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
    Br J Cancer. 2022;126:1027-1036.
    PubMed     Abstract available
    
    
    March 2022
41. YOU B, Van Wagensveld L, Tod M, Sonke GS, et al
    Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
    Br J Cancer. 2022 Mar 31. pii: 10.1038/s41416-022-01732.
    PubMed     Abstract available
    
    
    
42. REBOLJ M, Pesola F, Mathews C, Mesher D, et al
    The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot.
    Br J Cancer. 2022 Mar 26. pii: 10.1038/s41416-022-01791.
    PubMed     Abstract available
    
    
    
43. SEITZ S, Dreyer TF, Stange C, Steiger K, et al
    CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.
    Br J Cancer. 2022 Mar 21. pii: 10.1038/s41416-022-01763.
    PubMed     Abstract available
    
    
    
44. MORGAN RD, Burghel GJ, Flaum N, Bulman M, et al
    BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
    Br J Cancer. 2022 Mar 8. pii: 10.1038/s41416-022-01773.
    PubMed     Abstract available
    
    
    February 2022
45. ROQUE DM, Siegel ER, Buza N, Bellone S, et al
    Randomised phase II trial of weekly ixabepilone +/- biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
    Br J Cancer. 2022 Feb 11. pii: 10.1038/s41416-022-01717.
    PubMed     Abstract available
    
    
    January 2022
46. YE S, Li Q, Wu Y, Jiang W, et al
    Integrative genomic and transcriptomic analysis reveals immune subtypes and prognostic markers in ovarian clear cell carcinoma.
    Br J Cancer. 2022 Jan 18. pii: 10.1038/s41416-022-01705.
    PubMed     Abstract available
    
    
    
47. MUKAMA T, Fortner RT, Katzke V, Hynes LC, et al
    Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer.
    Br J Cancer. 2022 Jan 14. pii: 10.1038/s41416-021-01697.
    PubMed     Abstract available
    
    
    
48. SUN J, Yan C, Xu D, Zhang Z, et al
    Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.
    Br J Cancer. 2022 Jan 11. pii: 10.1038/s41416-021-01692.
    PubMed     Abstract available
    
    
    December 2021
49. FOTOPOULOU C, Rockall A, Lu H, Lee P, et al
    Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC).
    Br J Cancer. 2021 Dec 18. pii: 10.1038/s41416-021-01662.
    PubMed     Abstract available
    
    
    November 2021
50. BYUN D, Hong S, Ryu S, Nam Y, et al
    Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies.
    Br J Cancer. 2021 Nov 12. pii: 10.1038/s41416-021-01625.
    PubMed     Abstract available
    
    
    
51. DICK S, Vink FJ, Heideman DAM, Lissenberg-Witte BI, et al
    Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping.
    Br J Cancer. 2021 Nov 6. pii: 10.1038/s41416-021-01614.
    PubMed     Abstract available
    
    
    
52. GUFFANTI F, Alvisi MF, Anastasia A, Ricci F, et al
    Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    Br J Cancer. 2021 Nov 3. pii: 10.1038/s41416-021-01609.
    PubMed     Abstract available
    
    
    October 2021
53. MURPHY AD, Morgan RD, Clamp AR, Jayson GC, et al
    The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
    Br J Cancer. 2021 Oct 29. pii: 10.1038/s41416-021-01605.
    PubMed     Abstract available
    
    
    
54. BLACKFORD AL, Childs EJ, Porter N, Petersen GM, et al
    A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01580.
    PubMed     Abstract available
    
    
    
55. SI S, Li J, Tewara MA, Li H, et al
    Identifying causality, genetic correlation, priority and pathways of large-scale complex exposures of breast and ovarian cancers.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01576.
    PubMed     Abstract available
    
    
    
56. XIE SH, Santoni G, Lagergren J
    Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01575.
    PubMed     Abstract available
    
    
    September 2021
57. CRISPIN-ORTUZAR M, Sala E
    Precision radiogenomics: fusion biopsies to target tumour habitats in vivo.
    Br J Cancer. 2021;125:778-779.
    PubMed     Abstract available
    
    
    March 2021
58. EINBOND LS, Zhou J, Wu HA, Mbazor E, et al
    A novel cancer preventative botanical mixture, TriCurin, inhibits viral transcripts and the growth of W12 cervical cells harbouring extrachromosomal or integrated HPV16 DNA.
    Br J Cancer. 2021;124:901-913.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: